GYLDEN PHARMA LIMITED

Company Registration Number:
09955881 (England and Wales)

Unaudited abridged accounts for the year ended 31 March 2025

Period of accounts

Start date: 01 April 2024

End date: 31 March 2025

GYLDEN PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 31 March 2025

Balance sheet
Notes

GYLDEN PHARMA LIMITED

Balance sheet

As at 31 March 2025


Notes
2025
2024


£
£
Fixed assets
Intangible assets: 3 619,988 571,702
Tangible assets: 4 712,414 1,343,071
Investments: 5 809 811
Total fixed assets: 1,333,211 1,915,584
Current assets
Debtors:   316,825 4,078,144
Cash at bank and in hand: 294,382 464,852
Total current assets: 611,207 4,542,996
Creditors: amounts falling due within one year:   (4,120,784) (3,308,739)
Net current assets (liabilities): (3,509,577) 1,234,257
Total assets less current liabilities: (2,176,366) 3,149,841
Provision for liabilities: (1,161,037) (244,247)
Total net assets (liabilities): (3,337,403) 2,905,594
Capital and reserves
Called up share capital: 41 41
Share premium account: 47,984,873 47,127,444
Other reserves: 10,274,648 10,274,648
Profit and loss account: (61,596,965) (54,496,539)
Shareholders funds: (3,337,403) 2,905,594

The notes form part of these financial statements

GYLDEN PHARMA LIMITED

Balance sheet statements

For the year ending 31 March 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 31 December 2025
and signed on behalf of the board by:

Name: Thomas Rademacher
Status: Director

The notes form part of these financial statements

GYLDEN PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2025

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

GYLDEN PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2025

2. Employees

2025 2024
Average number of employees during the period 36 39

GYLDEN PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2025

3. Intangible Assets

Total
Cost £
At 01 April 2024 795,922
Additions 135,938
Disposals (18,394)
At 31 March 2025 913,466
Amortisation
At 01 April 2024 224,220
Charge for year 73,184
On disposals (3,926)
At 31 March 2025 293,478
Net book value
At 31 March 2025 619,988
At 31 March 2024 571,702

GYLDEN PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2025

4. Tangible Assets

Total
Cost £
At 01 April 2024 3,465,229
Additions 46,150
Disposals (1,082)
At 31 March 2025 3,510,297
Depreciation
At 01 April 2024 2,122,158
Charge for year 676,416
On disposals (691)
At 31 March 2025 2,797,883
Net book value
At 31 March 2025 712,414
At 31 March 2024 1,343,071

GYLDEN PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2025

5. Fixed investments

Fixed asset investments are initially recorded at cost, which is the purchase price plus any directly attributable transaction costs. Subsequently, they are measured at cost less any accumulated impairment losses. Income from investments, such as dividends, is recognized in the Profit and Loss account when the company's right to receive payment is established.